Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 9/20 | 0.61 |
| ▸ | MAOB | P27338 | 9/20 | 0.61 |
| ▸ | KDM1A | O60341 | 10/20 | 0.50 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28555751 | 0.79 | MAOA (0.44) | MAOAMAOBKDM1ARCOR1ALDH1A1 | |
| SCHEMBL1318340 | 0.76 | MAOA (1.00) | MAOAMAOBKDM1ARCOR1OPRM1 | |
| SCHEMBL23950417 | 0.76 | MAOA (0.42) | MAOAMAOBKDM1ARCOR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1318464 | 0.74 | MAOA (0.95) | MAOAMAOBKDM1ARCOR1OPRL1 | |
| SCHEMBL29214271 | 0.73 | HSD11B1 (0.41) | MAOAMAOBKDM1AALDH1A1 | |
| SCHEMBL7808357 | 0.73 | MAOA (0.52) | MAOAMAOBKDM1AOPRM1OPRL1 | |
| SCHEMBL5190756 | 0.72 | MAOA (0.83) | MAOAMAOBKDM1ARCOR1 | |
| Hydrochloric Acid SCHEMBL28716487 | 0.72 | MAOA (0.91) | MAOAMAOBKDM1ARCOR1OPRL1 | |
| SCHEMBL433971 | 0.72 | MAOA (0.83) | MAOAMAOBKDM1ARCOR1 | |
| SCHEMBL19212054 | 0.72 | KDM1A (0.61) | MAOAMAOBKDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | JANSSEN PHARMACEUTICA NV (BE) | 2023-06-29 | — | — | US | disclosed |
| WO-2021209552-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME PATHWAY | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203044-A1 | PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME | NLRP3, PYCARD, NLRP1 | MAOA 3283/4885MAOB 3722/4885KDM1A 1108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.